This rapid recommendation provides timely guidance on the use of olaparib. Submission for publication in the Journal of Clinical Oncology is forthcoming.2021 Updated Recommendation: The updated recommendation for June 2021 is -- For patients with early-stage, human epidermal growth factor receptor 2 (HER2)–negative breast cancer with high risk of recurrence and germline BRCA1 or BRCA2 pathogenic or likely pathogenic variants, one year of adjuvant olaparib should be offered after completion of (neo)adjuvant chemotherapy and local treatment, including radiation. For those who had surgery first, one year of adjuvant olaparib should be offered for patients with triple negative breast cancer (TNBC) and tumor size > 2 cm or any involved axillary nodes. For those with hormone receptor-positive disease, one year of adjuvant olaparib should be offered to those with at least four involved axillary lymph nodes. For patients who had neoadjuvant chemotherapy, one year of adjuvant olaparib should be offered to patients with TNBC and any residual cancer; for patients with hormone receptor-positive disease, one year of adjuvant olaparib should be offered to patients with residual disease and a clinical stage, pathologic stage, estrogen receptor status, and tumor grade (CSP+EG) score ≥ 3.